Authors:
SS Deen, AN Priest, MA McLean, AB Gill, C Brodie, R Crawford, J Latimer, P Baldwin, HM Earl, C Parkinson, S Smith, C Hodgkin, I Patterson, H Addley, S Freeman, P Moyle, M Jimenez-Linan, MJ Graves, E Sala, JD Brenton, FA Gallagher
Journal name: 
Sci Rep
Citation info: 
9(1):10742
Abstract: 
This study assessed the feasibility of using diffusion kurtosis imaging (DKI) as a measure of tissue heterogeneity and proliferation to predict the response of high grade serous ovarian cancer (HGSOC) to neoadjuvant chemotherapy (NACT). Seventeen patients with HGSOC were imaged at 3 T and had biopsy samples taken prior to any treatment. The patients were divided into two groups: responders and non-responders based on Response Evaluation Criteria In Solid Tumours (RECIST) criteria. The following imaging metrics were calculated: apparent diffusion coefficient (ADC), apparent diffusion (Dapp) and apparent kurtosis (Kapp). Tumour cellularity and proliferation were quantified using histology and Ki-67 immunohistochemistry. Mean Kapp before therapy was higher in responders compared to non-responders: 0.69 ± 0.13 versus 0.51 ± 0.11 respectively, P = 0.02. Tumour cellularity correlated positively with Kapp (rho = 0.50, P = 0.04) and negatively with both ADC (rho = -0.72, P = 0.001) and Dapp (rho = -0.80, P < 0.001). Ki-67 expression correlated with Kapp (rho = 0.53, P = 0.03) but not with ADC or Dapp. In conclusion, Kapp was found to be a potential predictive biomarker of NACT response in HGSOC, which suggests that DKI is a promising clinical tool for use oncology and radiology that should be evaluated further in future larger studies.
DOI: 
http://doi.org/10.1038/s41598-019-47195-4
Research group: 
Brenton Group
E-pub date: 
30 Jun 2019
Users with this publication listed: 
Evis Sala
Ferdia Gallagher
James Brenton
Mary McLean
Surrin Deen